KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Invested Capital (2023 - 2025)

Biocryst Pharmaceuticals' Invested Capital history spans 9 years, with the latest figure at -$116.4 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 75.34% year-over-year to -$116.4 million; the TTM value through Dec 2025 reached -$116.4 million, up 75.34%, while the annual FY2025 figure was -$116.4 million, 75.34% up from the prior year.
  • Invested Capital reached -$116.4 million in Q4 2025 per BCRX's latest filing, up from -$384.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of -$87.8 million in Q1 2023 to a low of -$472.0 million in Q1 2024.
  • Average Invested Capital over 3 years is -$362.1 million, with a median of -$432.9 million recorded in 2025.
  • Peak YoY movement for Invested Capital: plummeted 437.39% in 2024, then skyrocketed 75.34% in 2025.
  • A 3-year view of Invested Capital shows it stood at -$451.1 million in 2023, then fell by 4.63% to -$472.0 million in 2024, then surged by 75.34% to -$116.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Invested Capital are -$116.4 million (Q4 2025), -$384.7 million (Q3 2025), and -$417.9 million (Q2 2025).